Keith Orford brings to Parabilis Medicines three decades of experience in oncology research, spanning the basic, translational and clinical domains. As chief medical officer and executive vice president of clinical and translational science, he oversees the translational medicine and clinical development initiatives for Parabilis Medicines.

Prior to joining Parabilis Medicines, Keith was the chief medical officer of Calithera Biosciences, where he led the clinical group, including clinical development, clinical operations, biometrics, pharmacovigilance and medical affairs. Prior to Calithera, Keith was the clinical development lead in the immuno-oncology and combinations development performance unit at GlaxoSmithKline, where he oversaw clinical development, including multiple early-stage clinical trials with targeted agents and immunotherapies. Before GlaxoSmithKline, Keith was at Merck, where he worked on early clinical development programs across therapeutic areas. Previously, he was a research fellow and instructor at Massachusetts General Hospital and Harvard Medical School, where he trained in internal medicine and completed a postdoctoral fellowship in the laboratory of Dr. David Scadden, studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation.

Keith holds his undergraduate, M.D. and Ph.D. degrees from Georgetown University. His Ph.D. research elucidated the mechanism by which b-catenin is regulated by the Wnt signaling pathway.